Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Brief Genetics Report

The Human Peroxisome Proliferator-Activated Receptor γ2 (PPARγ2) Pro12Ala Polymorphism Is Associated With Decreased Risk of Diabetic Nephropathy in Patients With Type 2 Diabetes

  1. Maria Luiza Caramori,
  2. Luis Henrique Canani,
  3. Luciana A. Costa and
  4. Jorge Luiz Gross
  1. From the Endocrine Division, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
  1. Address correspondence and reprint requests to Jorge Luiz Gross, MD, Endocrine Division, Hospital de Clínicas de Porto Alegre, Ramiro Barcellos 2350, Prédio 12, 4° Andar, Porto Alegre, RS, Brazil 90035-003. E-mail: jorgegross{at}terra.com.br
Diabetes 2003 Dec; 52(12): 3010-3013. https://doi.org/10.2337/diabetes.52.12.3010
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

The peroxisome proliferator-activated receptor γ2 (PPARγ2) Pro12Ala polymorphism has been associated with a decreased risk of type 2 diabetes and a lower albumin excretion rate (AER) in patients with established diabetes. We performed a case-control study aiming to evaluate the association between the Pro12Ala polymorphism and diabetic nephropathy. Genomic DNA was obtained from 104 type 2 diabetic patients (case subjects) with chronic renal insufficiency (78 on dialysis and 26 with proteinuria [AER ≥200 μg/min] and serum creatinine ≥2.0 mg/dl) and 212 normoalbuminuric patients (AER <20 μg/min) with known diabetes duration ≥10 years (control subjects). The genotypic distribution of the PPARγ2 Pro12Ala polymorphism in these diabetic patients was in Hardy-Weinberg equilibrium, and the Ala allele frequency was 9%. The frequency of Ala carriers (Ala/Ala or Ala/Pro) was 20.3% in control subjects and 10.6% in case subjects (P = 0.031). The odds ratio of having diabetic nephropathy for Ala carriers was 0.465 (95% CI 0.229–0.945; P = 0.034). Carriers of the Ala allele were not different from noncarriers (Pro/Pro) regarding sex (38.9 vs. 44.1% males) or ethnicity (77.4 vs. 71.7% white) distribution, age (61 ± 10 vs. 61 ± 10 years), known diabetes duration (17 ± 7 vs. 16 ± 7 years), BMI (27 ± 4 vs. 28 ± 5 kg/m2), fasting plasma glucose (184 ± 81 vs. 176 ± 72 mg/dl), HbA1c (6.7 ± 2.3 vs. 6.9 ± 2.4%; high-performance liquid chromatography reference range: 2.7–4.3%), and systolic (145 ± 27 vs. 0.144 ± 24 mmHg) or diastolic (87 ± 14 vs. 85 ± 14 mmHg) blood pressure, respectively. In conclusion, the presence of the Ala allele may confer protection from diabetic nephropathy in patients with type 2 diabetes.

  • AER, albumin excretion rate
  • ESRD, end-stage renal disease
  • PPARγ, peroxisome proliferator-activated receptor γ

Diabetic nephropathy is the main cause of end-stage renal disease (ESRD) in the U.S. (1) and western Europe (2) and is responsible for almost half of new ESRD cases. About 80% of these ESRD patients have type 2 diabetes (1,3). It is, therefore, important to identify markers of diabetic nephropathy risk in these patients. A polymorphism in the gene for peroxisome proliferator-activated receptor γ (PPARγ), a nuclear transcription factor involved in adipocyte differentiation, glucose and lipid metabolism, and fatty acid transport (4), has been associated with decreased risk of type 2 diabetes (5,6) and with lower albumin excretion rate (AER) in patients with established type 2 diabetes (7). Here, we evaluated the association between PPARγ2 Pro12Ala polymorphism and diabetic nephropathy in patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS

A case-control study was conducted in 316 patients with type 2 diabetes (according to World Health Organization criteria) (8) who were selected from a sample of >1,200 patients participating in a multicenter research protocol in the Rio Grande do Sul state (Brazil). The aim was to identify the genetic and nongenetic risk factors associated with diabetes complications. All type 2 diabetic patients with proteinuria (AER >200 μg/min) and serum creatinine >2.0 mg/dl and all patients with normoalbuminuria (AER <20 μg/min) and known diabetes duration of at least 10 years were studied. The 104 proteinuric patients with serum creatinine >2.0 mg/dl (78 on dialysis) were defined as case subjects, and the 212 normoalbuminuric patients with a known diabetes duration of at least 10 years were defined as control subjects.

This study was approved by the ethics committee of the Hospital de Clínicas de Porto Alegre and the corresponding committees at the institutions from which DNA samples were obtained. Written informed consent was obtained from all participants.

Patients underwent a standardized clinical and laboratory evaluation that, to summarize, consisted of a questionnaire, physical examination, and blood collection. Sitting blood pressure was measured twice to the nearest 2 mmHg after a 5-min rest using a standard mercury sphygmomanometer (phases I and V of Korotkoff). The mean value of three measurements was used to calculate systolic and diastolic blood pressure. Hypertension was defined as blood pressure levels ≥140/90 mmHg (9) or the use of antihypertensive medication. Retinopathy was assessed by ophthalmoscopic examination through dilated pupils in 293 patients and classified as absent, nonproliferative, or proliferative. AER was measured in 24-h timed sterile urine samples by immunoturbidimetry (Sera-Pak immuno microalbuminuria; Bayer, Tarrytown, NY). AER values ≥200 μg/min were confirmed in a second urine sample. Glucose was measured by the glucose oxidase method, HbA1c by an ion exchange high-performance liquid chromatography (Merck-Hitachi L-9100 GhB analyzer, reference range 2.7–4.3; Merck, Darmstadt, Germany) and serum creatinine by Jaffé’s reaction.

Genotyping.

Genomic DNA was extracted from peripheral blood. The PPARγ2 Pro12Ala polymorphism was detected as described elsewhere (10). The PCR products were digested overnight at 37°C with BstU-1 enzyme, electrophoresed on a 2.5% agarose gel, and stained with ethidium bromide. The expected products after digestion were 270 bp for normal homozygous (Pro/Pro), 227 bp and 43 bp for Pro12Ala homozygous (Ala/Ala), and 270 bp, 227 bp, and 43 bp for heterozygous (Pro/Ala). The frequency of the Ala allele was 10.0% in white and 7.5% in nonwhite volunteer blood donors (P = 0.357).

Statistical analysis.

The clinical and laboratory characteristics of the case and control subjects were compared by unpaired Student’s t test or χ2 test, as appropriate. Genotype distribution in the case and control subjects was compared by χ2 test. Multiple logistic regression analysis was used to determine the independent factors associated with diabetic nephropathy. Data are expressed as mean ± SD or as number of patients with a given characteristic. Triglycerides, not normally distributed, were logarithmically transformed before analysis and are presented as median and range. The test for Hardy-Weinberg equilibrium was performed as previously described (11). P values <0.05 were considered significant. SPSS version 10.0 (SPSS, Chicago, IL) was used for the analyses.

RESULTS

Patients with diabetic nephropathy (case subjects) were more often men (P < 0.0001) and, as expected, more often hypertensive (P < 0.0001) than long-standing normoalbuminuric patients (control subjects) (Table 1). There was no difference in the proportion of patients using antihypertensive drugs between case (72.9%) and control (64.3%; P = 0.241) subjects. However, case subjects used ACE inhibitors or angiotensin receptor blockers more often (47.2%) than control subjects (29.2%; P = 0.013). Diabetic retinopathy was also more frequent in case (88% with any retinopathy, 72% with proliferative retinopathy) than in control (42% with any retinopathy, 7% with proliferative retinopathy; P < 0.001) subjects. Diabetes treatment in case and control subjects consisted of diet (16.9 vs. 3.2%), oral agents (16.9 vs. 55.2%), or insulin (66.2 vs. 41.6%; P < 0.001), respectively. None of the patients included in this study were using thiazolidonedione compounds.

The genotypic distribution of the PPARγ2 Pro12Ala gene polymorphism was in Hardy-Weinberg equilibrium. The frequency of the Ala allele in these type 2 diabetic patients was 9%. The frequency of Ala carriers (Ala/Ala and Pro/Ala) was higher among normoalbuminuric (20.3%) than diabetic nephropathy (10.6%; P = 0.031) patients. The Ala allele was also more frequent in control subjects (10.8%) than in diabetic nephropathy case subjects (5.8%; P = 0.038). There was no difference in the Ala allele frequency between patients with chronic renal insufficiency (11.5%) and patients on dialysis (10.3%). The odds ratio (OR) of having diabetic nephropathy for Ala allele carriers was 0.465 compared with noncarriers (95% CI 0.229–0.945; P = 0.034). Multiple logistic regression analysis showed that Ala carriers (OR 0.425 [95% CI 0.196–0.974]; P = 0.043) and male sex (3.94 [2.30–6.76]; P < 0.001) were independently associated with diabetic nephropathy. These results did not change when normoalbuminuric patients using ACE inhibitors or angiotensin receptor blockers or nonwhite patients were excluded from the analyses.

There were no differences between Ala carriers and noncarriers regarding age, diabetes duration, sex distribution, BMI, waist-to-hip ratio, fasting plasma glucose, HbA1c, total cholesterol, triglycerides, serum creatinine, and blood pressure levels (Table 2). Also, there was no difference regarding antihypertensive use (63.3 vs. 68.8%; P = 0.558) or ACE inhibitor or angiotensin receptor blocker use (29.4 vs. 37.7%; P = 0.361) between Ala carriers and noncarriers, respectively. There was no difference in the antihyperglycemic regimen used by Ala carriers (10.3% diet, 51.3% oral agents, and 38.5% insulin) or noncarriers (7.3% diet, 40.6% oral agents, and 52.1% insulin; P = 0.295).

DISCUSSION

The decreased risk of diabetic nephropathy among PPARγ2 Ala12 allele carriers suggests that this genetic variation in PPARγ2 has a protective role in relation to the risk of diabetic nephropathy in patients with type 2 diabetes. This confirms and extends the observations that Caucasian type 2 diabetic PPARγ2 Pro12Ala carriers have lower AER levels (7) and, presumably, lower diabetic nephropathy risk. Although no difference in the frequency of Ala allele carriers was observed between normoalbuminuric and ESRD patients (7), this latter study was underpowered to detect this association because only a small number of ESRD patients (n = 44) were evaluated. Further, some of the normoalbuminuric patients may have had a short diabetes duration (interquartile diabetes duration ranging from 4 to 17 years) (7) and may, in fact, be at risk of progressing to diabetic nephropathy (12). The association between the PPARγ2 Pro12Ala polymorphism and macroalbuminuria, seen only when patients with diabetes duration ≥20 years were analyzed (7), is in agreement with this thesis. A large study of Japanese type 2 diabetic patients did not find association between diabetic nephropathy and the PPARγ2 Pro12Ala polymorphism (13). However, diabetic nephropathy in this study (13) was defined as an AER >10 μg/ml. This could have led to patients with clinically insignificant diabetic renal involvement being included in the diabetic nephropathy group (13).

The mechanisms by which the PPARγ2 Pro12Ala polymorphism could lead to diabetic nephropathy are unknown. The PPARγ2 Pro12Ala polymorphism has been associated with higher insulin sensitivity (5,14) and decreased risk of type 2 diabetes (6,10,13–17). Since insulin resistance may be a risk factor for diabetic nephropathy in type 2 diabetes (18,19), improved insulin sensitivity could be the link between the PPARγ2 Pro12Ala polymorphism and decreased risk of diabetic nephropathy. It would also be reasonable to hypothesize that the diabetic nephropathy protective effect of the PPARγ2 Pro12Ala polymorphism could be dependent on a decreased risk of hypertension among Ala carriers versus noncarriers. However, there was no difference in the frequency of hypertension between Ala carriers and noncarriers in the current study. Another possibility would be that this polymorphism could modulate the harmful effects of hypertension in the kidney by altering, for example, the expression of plasminogen activator inhibitor 1 and transforming growth factor-β.

However, caution needs to be exercised when interpreting the results of the present study because association studies require special attention in their design (20,21). It is particularly important to have an appropriate sample size, allowing the detection of true differences between groups, and to adopt strict selection criteria in order to include in the study only patients with well-defined phenotypes (20). In this regard, the current study evaluated a large sample of carefully characterized type 2 diabetic patients, selecting as control subjects only normoalbuminuric patients with a long diabetes duration and as case subjects only patients with clearly established diabetic nephropathy. A possible limitation of the current report would be the inclusion of some patients in the normoalbuminuric group who were, in fact, microalbuminuric patients that had their AER reduced by the use of ACE inhibitors or angiotensin receptor blockers. Nonetheless, as argued above, the association between PPARγ2 Pro12Ala polymorphism and diabetes complications risk seems to make biological sense. Moreover, this association has been previously reported by Herrmann et al. (7) in a study that found lower AER levels among Ala carriers in a large sample of Caucasian type 2 diabetic patients, indicating a protective effect of the Ala12 allele in relation to diabetic nephropathy.

In conclusion, the presence of the Ala allele of the PPARγ2 Pro12Ala polymorphism is associated with a decreased risk of diabetic nephropathy in patients with type 2 diabetes. This association needs to be confirmed in other patient populations. More basic studies will be required to uncover the molecular mechanisms underlying the association between PPARγ2 Pro12Ala polymorphism and diabetic nephropathy risk.

View this table:
  • View inline
  • View popup
TABLE 1

Clinical and laboratory characteristics of type 2 diabetic patients with normoalbuminuria (control subjects) or with diabetic nephropathy (case subjects)

View this table:
  • View inline
  • View popup
TABLE 2

Clinical and laboratory characteristics of type 2 diabetic patients according to the presence (Ala/Ala and Pro/Ala) or not (Pro/Pro) of the Ala allele

Acknowledgments

This work was partially supported by grants from Projeto de Núcleo de Excelência do Ministério de Ciência e Tecnologia and Hospital de Clínicas de Porto Alegre. L.A.C. was a recipient of a scholarship from Fundação Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior.

We thank Paula Eichler and Emanuele Kuhn for technical support and Professor Michael Mauer for his thoughtful comments.

Footnotes

    • Accepted September 8, 2003.
    • Received April 29, 2003.
  • DIABETES

REFERENCES

  1. ↵
    US Renal Data System: U.S. Renal Data System: 1999 Annual Report. Bethesda, MD, National Institute of Diabetes and Digestive and Kidney Diseases,1999
  2. ↵
    Rychlik I, Miltenberger-Miltenyi G, Ritz E: The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol Dial Transplant 13 : 6 –10,1998
    OpenUrlFREE Full Text
  3. ↵
    Bruno RM, Gross JL: Prognostic factors in Brazilian diabetic patients starting dialysis: a 3.6-year follow-up study. J Diabetes Complications 14 : 266 –271,2000
    OpenUrlPubMed
  4. ↵
    Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, Lehmann JM: The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39 : 665 –668,1996
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20 : 284 –287,1998
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES: The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26 : 76 –80,2000
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    Herrmann SM, Ringel J, Wang JG, Staessen JA, Brand E: Peroxisome proliferator-activated receptor-γ2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) study. Diabetes 51 : 2653 –2657,2002
    OpenUrlAbstract/FREE Full Text
  8. ↵
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 26 (Suppl. 1) : S5 –S20,2003
  9. ↵
    The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 157 : 2413 –2446,1997
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yarnall DP, Burns DK, Roth J, Shuldiner AR: Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241 : 270 –274,1997
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    Weir BS: Genetic Data Analysis II. Boston, MA, Sinauer Associates,1996
  12. ↵
    Caramori ML, Fioretto P, Mauer M: The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 49 : 1399 –1408,2000
    OpenUrlAbstract
  13. ↵
    Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M: The Pro12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes 50 : 891 –894,2001
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Poulsen P, Andersen G, Fenger M, Hansen T, Echwald SM, Volund A, Beck-Nielsen H, Pedersen O, Vaag A: Impact of two common polymorphisms in the PPAR-γ gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both? Diabetes 52 : 194 –198,2003
    OpenUrlAbstract/FREE Full Text
  15. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T: The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271 : 212 –216,2000
    OpenUrlCrossRefPubMedWeb of Science
  16. Ardlie KG, Lunetta KL, Seielstad M: Testing for population subdivision and association in four case-control studies. Am J Hum Genet 71 : 304 –311,2002
    OpenUrlCrossRefPubMedWeb of Science
  17. ↵
    Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA, Bergman RN, Collins FS, Boehnke M, Tuomilehto J: The peroxisome proliferator-activated receptor-γ2 Pro12A1a variant: association with type 2 diabetes and trait differences. Diabetes 50 : 886 –890,2001
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Isomaa B, Henricsson M, Almgren P, Tuomi T, Taskinen MR, Groop L: The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 44 : 1148 –1154,2001
    OpenUrlCrossRefPubMedWeb of Science
  19. ↵
    Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE: Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities? Further evidence from the Pittsburgh Epidemiology of Diabetes Complication Study. Kidney Int 62 : 963 –970,2002
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Freely associating. Nat Genet 22 : 1 –2,1999
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Hirschhorn JN, Altshuler D: Once and again: issues surrounding replication in genetic association studies. J Endocrinol Metab 87 : 4438 –4441,2002
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top

In this Issue

December 2003, 52(12)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Human Peroxisome Proliferator-Activated Receptor γ2 (PPARγ2) Pro12Ala Polymorphism Is Associated With Decreased Risk of Diabetic Nephropathy in Patients With Type 2 Diabetes
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The Human Peroxisome Proliferator-Activated Receptor γ2 (PPARγ2) Pro12Ala Polymorphism Is Associated With Decreased Risk of Diabetic Nephropathy in Patients With Type 2 Diabetes
Maria Luiza Caramori, Luis Henrique Canani, Luciana A. Costa, Jorge Luiz Gross
Diabetes Dec 2003, 52 (12) 3010-3013; DOI: 10.2337/diabetes.52.12.3010

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

The Human Peroxisome Proliferator-Activated Receptor γ2 (PPARγ2) Pro12Ala Polymorphism Is Associated With Decreased Risk of Diabetic Nephropathy in Patients With Type 2 Diabetes
Maria Luiza Caramori, Luis Henrique Canani, Luciana A. Costa, Jorge Luiz Gross
Diabetes Dec 2003, 52 (12) 3010-3013; DOI: 10.2337/diabetes.52.12.3010
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Association of the Diabetes Gene Calpain-10 With Subclinical Atherosclerosis
  • The Rat Diabetes Susceptibility Locus Iddm4 and at Least One Additional Gene Are Required for Autoimmune Diabetes Induced by Viral Infection
  • Genetic Variation at the ACE Gene Is Associated With Persistent Microalbuminuria and Severe Nephropathy in Type 1 Diabetes
Show more Brief Genetics Report

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.